{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:26:24Z","timestamp":1788409584179,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Australian National Health and Medical Research Council Emerging Leadership Investigator Grant","award":["GNT1193955"],"award-info":[{"award-number":["GNT1193955"]}]},{"name":"the Australian National Health and Medical Research Council Emerging Leadership Investigator Grant","award":["GNT1193955"],"award-info":[{"award-number":["GNT1193955"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recommended first-line treatment for <jats:italic>Mycoplasma genitalium<\/jats:italic> infections is azithromycin. However, the prevalence of macrolide resistance for <jats:italic>M. genitalium<\/jats:italic> has increased to more than 50% worldwide. In 2013, Australia introduced a resistance-guided therapy (RGT) strategy to manage <jats:italic>M. genitalium<\/jats:italic> infections. This study assesses the cost-effectiveness of the RGT approach compared to no RGT (i.e., without macrolide resistance profile test) in women, men who have sex with men (MSM), and men who have sex with women (MSW) in Australia. We constructed dynamic transmission models of <jats:italic>M. genitalium<\/jats:italic> infections in women, MSM, and MSW in Australia, each with a population of 100,000. These models compared the costs and quality-adjusted life-years (QALYs) gained between RGT and no RGT scenarios from a healthcare perspective over ten years. All costs are reported in 2022 Australian dollars (Australian $). In our model, RGT is cost saving in women and MSM, with the incremental net monetary benefit of $1.3 million and $17.9 million, respectively. In MSW, the RGT approach is not cost-effective, with an incremental cost-effectiveness ratio of -$106.96 per QALY gained. RGT is cost saving compared to no RGT for <jats:italic>M. genitalium<\/jats:italic> infections in women and MSM, supporting its adoption as the national management strategy for these two population groups.<\/jats:p>","DOI":"10.1038\/s41598-024-63056-1","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T17:05:38Z","timestamp":1717520738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cost-effectiveness of resistance-guided therapy for Mycoplasma genitalium in Australia"],"prefix":"10.1038","volume":"14","author":[{"given":"Rabiah Al","family":"Adawiyah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona S.","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka A.","family":"Vodstrcil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Fairley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"63056_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1136\/sextrans-2017-053384","volume":"94","author":"L Baumann","year":"2018","unstructured":"Baumann, L. et al. Prevalence of Mycoplasma genitalium in different population groups: Systematic review and meta-analysis. Sex. Transm. Infect 94, 254\u2013261 (2018).","journal-title":"Sex. Transm. Infect"},{"key":"63056_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/J.ECLINM.2021.100779\/ATTACHMENT\/1F5B9325-A64E-4904-B53A-4136AB5C1992\/MMC1.DOCX","author":"TRH Read","year":"2021","unstructured":"Read, T. R. H. et al. Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model. EClinicalMedicine https:\/\/doi.org\/10.1016\/J.ECLINM.2021.100779\/ATTACHMENT\/1F5B9325-A64E-4904-B53A-4136AB5C1992\/MMC1.DOCX (2021).","journal-title":"EClinicalMedicine"},{"key":"63056_CR3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1086\/656739","volume":"51","author":"P Oakeshott","year":"2010","unstructured":"Oakeshott, P. et al. Is Mycoplasma genitalium in women the \u2018new chlamydia?\u2019 A community-based prospective cohort study. Clin. Infect. Dis. 51, 1160\u20131166 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"63056_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv194","author":"P Sonnenberg","year":"2015","unstructured":"Sonnenberg, P. et al. Epidemiology of Mycoplasma genitalium in British men and women aged 16\u201344 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Int. J. Epidemiol. https:\/\/doi.org\/10.1093\/ije\/dyv194 (2015).","journal-title":"Int. J. Epidemiol."},{"key":"63056_CR5","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/cid\/ciad405","volume":"77","author":"LE Manhart","year":"2023","unstructured":"Manhart, L. E. et al. Mycoplasma genitalium in the US (MyGeniUS): Surveillance data from sexual health clinics in 4 US regions. Clin. Infect. Dis. 77, 1449\u20131459 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"63056_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/sextrans-2017-053384","volume":"94","author":"L Baumann","year":"2018","unstructured":"Baumann, L. et al. Prevalence of Mycoplasma genitalium in different population groups: Systematic review and meta-analysis. Sex. Transm. Infect. 94, 255\u2013262 (2018).","journal-title":"Sex. Transm. Infect."},{"key":"63056_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3201\/eid2504.181258","volume":"25","author":"TRH Read","year":"2019","unstructured":"Read, T. R. H. et al. Symptoms, Sites, and Significance of Mycoplasma genitalium in Men Who Have Sex with Men. Emerg. Infect. Dis. 25, 719\u2013727 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"63056_CR8","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1093\/cid\/cir702","volume":"53","author":"LE Manhart","year":"2011","unstructured":"Manhart, L. E., Broad, J. M. & Golden, M. R. Mycoplasma genitalium: Should we treat and how?. Clin Infect Dis 53, S129\u2013S142 (2011).","journal-title":"Clin Infect Dis"},{"key":"63056_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001324","volume":"7","author":"CL McGowin","year":"2011","unstructured":"McGowin, C. L. & Anderson-Smits, C. Mycoplasma genitalium: An emerging cause of sexually transmitted disease in women. PLoS Pathog. 7, e1001324 (2011).","journal-title":"PLoS Pathog."},{"key":"63056_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/cid\/civ312","volume":"61","author":"R Lis","year":"2015","unstructured":"Lis, R., Rowhani-Rahbar, A. & Manhart, L. E. Mycoplasma genitalium infection and female reproductive tract disease: A meta-analysis. Clin. Infect. Dis. 61, 418\u2013426 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"63056_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cmi.2015.11.016","volume":"22","author":"M Bissessor","year":"2016","unstructured":"Bissessor, M. et al. The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men. Clin. Microbiol. Infect 22, 260\u2013265 (2016).","journal-title":"Clin. Microbiol. Infect"},{"key":"63056_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/OLQ.0000000000000793","volume":"45","author":"JJ Ong","year":"2018","unstructured":"Ong, J. J. et al. Clinical characteristics of anorectal Mycoplasma genitalium infection and microbial cure in men who have sex with men. Sex. Transm. Dis. 45, 522\u2013526 (2018).","journal-title":"Sex. Transm. Dis."},{"key":"63056_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/jdv.17972","volume":"36","author":"JS Jensen","year":"2022","unstructured":"Jensen, J. S. et al. 2021 European guideline on the management of Mycoplasma genitalium infections. J. Eur. Acad. Dermatol. Venereol. 36, 641\u2013650 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"63056_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1071\/SH22134","volume":"20","author":"JJ Ong","year":"2023","unstructured":"Ong, J. J. et al. Australian sexually transmitted infection (STI) management guidelines for use in primary care 2022 update. Sex Health 20, 1\u20138 (2023).","journal-title":"Sex Health"},{"key":"63056_CR15","doi-asserted-by":"publisher","first-page":"100779","DOI":"10.1016\/j.eclinm.2021.100779","volume":"33","author":"JJ Ong","year":"2021","unstructured":"Ong, J. J. et al. Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model. EClinicalMedicine 33, 100779. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100779 (2021).","journal-title":"EClinicalMedicine"},{"key":"63056_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/cid\/ciy477","volume":"68","author":"TRH Read","year":"2019","unstructured":"Read, T. R. H. et al. Clinical infectious diseases outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: A prospective evaluation. Clin. Infect. Dis. 68, 554\u2013560 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"63056_CR17","first-page":"277","volume":"98","author":"RL Latimer","year":"2022","unstructured":"Latimer, R. L. et al. The clinical indications for testing women for Mycoplasma genitalium. Sex. Transm. Infect. 98, 277\u2013285 (2022).","journal-title":"Sex. Transm. Infect."},{"key":"63056_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/sextrans-2020-054695","volume":"98","author":"HS Shilling","year":"2022","unstructured":"Shilling, H. S. et al. Chlamydia trachomatis and Mycoplasma genitalium prevalence and associated factors among women presenting to a pregnancy termination and contraception clinic, 2009\u20132019. Sex. Transm. Infect. 98, 115\u2013120 (2022).","journal-title":"Sex. Transm. Infect."},{"key":"63056_CR19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","volume":"20","author":"DA Machalek","year":"2020","unstructured":"Machalek, D. A. et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: A systematic review and meta-analysis. Lancet Infect. Dis. 20, 1302\u20131314 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"63056_CR20","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/cid\/ciz1031","volume":"71","author":"D Durukan","year":"2020","unstructured":"Durukan, D. et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline\u20132.5 g azithromycin for the treatment of Mycoplasma genitalium infection: Efficacy and tolerability. Clin. Infect. Dis. 71, 1461\u20131468 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"63056_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrurol.2016.268","volume":"14","author":"M Unemo","year":"2017","unstructured":"Unemo, M. & Jensen, J. S. Antimicrobial-resistant sexually transmitted infections: Gonorrhoea and Mycoplasma genitalium. Nat. Rev. Urol. 14, 139\u2013152 (2017).","journal-title":"Nat. Rev. Urol."},{"key":"63056_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/cid\/cis1210","volume":"56","author":"J Walker","year":"2013","unstructured":"Walker, J. et al. Mycoplasma genitalium incidence, organism load, and treatment failure in a cohort of young Australian women. Clin. Infect. Dis. 56, 1094\u20131100 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"63056_CR23","doi-asserted-by":"publisher","first-page":"S396","DOI":"10.1093\/infdis\/jix145","volume":"216","author":"PJ Horner","year":"2017","unstructured":"Horner, P. J. & Martin, D. H. Mycoplasma genitalium Infection in Men. J. Infect. Dis. 216, S396 (2017).","journal-title":"J. Infect. Dis."},{"key":"63056_CR24","first-page":"20","volume":"2023","author":"D Husereau","year":"2022","unstructured":"Husereau, D. et al. (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. BM Med. 2023, 20 (2022).","journal-title":"BM Med."},{"key":"63056_CR25","doi-asserted-by":"publisher","first-page":"960","DOI":"10.3201\/eid2106.141270","volume":"21","author":"K Owusu-Edusei","year":"2015","unstructured":"Owusu-Edusei, K., Chesson, H. W., Gift, T. L., Brunham, R. C. & Bolan, G. Cost-effectiveness of chlamydia vaccination programs for young women. Emerg. Infect. Dis. 21, 960 (2015).","journal-title":"Emerg. Infect. Dis."},{"key":"63056_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/183167","volume":"2014","author":"S Ljubin-Sternak","year":"2014","unstructured":"Ljubin-Sternak, S. & Me\u0161trovi\u0107, T. Chlamydia TRACHOMATIS and genital mycoplasmas: Pathogens with an impact on human reproductive health. J. Pathog. 2014, 1\u201315 (2014).","journal-title":"J. Pathog."},{"key":"63056_CR27","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/1471-0528.13567","volume":"123","author":"JJ Ong","year":"2016","unstructured":"Ong, J. J. et al. Chlamydia screening for pregnant women aged 16\u201325 years attending an antenatal service: A cost-effectiveness study. BJOG An. Int. J. Obstet. Gynaecol. 123, 1194\u20131202 (2016).","journal-title":"BJOG An. Int. J. Obstet. Gynaecol."},{"key":"63056_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1473-3099(21)00629-0","volume":"22","author":"EL Sweeney","year":"2022","unstructured":"Sweeney, E. L., Bradshaw, C. S., Murray, G. L. & Whiley, D. M. Individualised treatment of Mycoplasma genitalium infection-incorporation of fluoroquinolone resistance testing into clinical care. Lancet Infect. Dis. 22, 367\u2013370 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"63056_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/OLQ.0000000000001177","volume":"47","author":"M Fern\u00e1ndez-Huerta","year":"2020","unstructured":"Fern\u00e1ndez-Huerta, M., Serra-Pladevall, J., Pich, O. Q., Barber\u00e1, M. J. & Espasa, M. From resistance-guided to risk-guided antimicrobial therapy in Mycoplasma genitalium. Sex. Transm. Dis. 47, 409\u2013411 (2020).","journal-title":"Sex. Transm. Dis."},{"key":"63056_CR30","doi-asserted-by":"crossref","unstructured":"Chua T. Evolving antimicrobial resistance in\u00a0Mycoplasma\u00a0genitalium: an updated global systematic review and meta-analysis. 2023.","DOI":"10.2139\/ssrn.4764790"},{"key":"63056_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/cid\/ciab1058","volume":"75","author":"LA Vodstrcil","year":"2022","unstructured":"Vodstrcil, L. A. et al. Combination therapy for Mycoplasma genitalium, and new insights into the utility of parC mutant detection to improve cure. Clin. Infect. Dis. 75, 813\u2013823 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"63056_CR32","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1038\/s41598-020-60179-z","volume":"10","author":"JLC Borgogna","year":"2020","unstructured":"Borgogna, J. L. C. et al. The association of Chlamydia trachomatis and Mycoplasma genitalium infection with the vaginal metabolome. Sci. Rep. 10, 3420 (2020).","journal-title":"Sci. Rep."},{"key":"63056_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu, X. et al. Modelling the multiple anatomical site transmission of Mycoplasma genitalium among men who have sex with men in Australia. Sci. Rep. 11, 1\u20138 (2021).","journal-title":"Sci. Rep."},{"key":"63056_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa291","author":"M Doyle","year":"2020","unstructured":"Doyle, M. et al. Nonquinolone options for the treatment of Mycoplasma genitalium in the era of increased resistance. Open Forum. Infect. Dis. https:\/\/doi.org\/10.1093\/ofid\/ofaa291 (2020).","journal-title":"Open Forum. Infect. Dis."},{"issue":"6","key":"63056_CR35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/sextrans-2022-055611","volume":"99","author":"JJ Ong","year":"2023","unstructured":"Ong, J. J. et al. Cost-effectiveness of testing for Mycoplasma genitalium among men who have sex with men in Australia. Sex. Transm. Infect. 99(6), 398\u2013403. https:\/\/doi.org\/10.1136\/sextrans-2022-055611 (2023).","journal-title":"Sex. Transm. Infect."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63056-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T17:12:45Z","timestamp":1717521165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-63056-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["63056"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-63056-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"21 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RA, LZ and LV declare no competing interests. JO, CB and CKF reports financial support was provided by Australian National Health and Medical Research Council. CB receives federal funding from an Australian Research Council Industrial Research Transformation Hub grant and her institution has received diagnostic kits for research on M. genitalium from both Speedx pty ltd and Cepheid Pty Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12856"}}